On November 17, 2026, Science Corporation announced that it had raised $400 million in a Series D round to expand availability of its PRIMA retinal implant in Europe and prepare for a US launch. Total funding since the company's founding in 2021 now exceeds $900 million. The company plans to use the new money to build out research and development, manufacturing, and operations, and also to support separate biohybrid research using cultured neurons. TechCrunch, citing a person familiar with the deal, reported that the round values the company at $3.5 billion.

PRIMA is a device that helps patients with advanced atrophic age-related macular degeneration, whose central vision has been damaged, to read text. It combines a chip implanted under the retina with special glasses to supplement vision. However, visual acuity results vary with how the glasses are used, so it is important to distinguish vision restored by the device itself from assistance provided by features such as image magnification.

AD

How can vision lost at the center of the retina be supplemented?

In geographic atrophy associated with atrophic age-related macular degeneration, the photoreceptors that capture light are lost in the central retina. A dark spot appears where the patient looks, while peripheral vision may be preserved. PRIMA works by placing a photovoltaic implant under the retina in the atrophied area and transmitting electrical signals to the remaining retinal bipolar cells.

Images are captured by a camera mounted on transparent special glasses. A portable unit processes the footage, and a projector on the glasses beams near-infrared light with a wavelength of 880 nm onto the chip under the retina. The chip measures 2 × 2 mm, is 30 µm thick, and has 378 pixels, each 100 µm in size. Each pixel converts the light it receives into an electrical pulse that stimulates bipolar cells. After the signal is processed within the retina, it travels through the optic nerve to the brain.

The chip supplements the central part of the visual field. The lenses of the special glasses are transparent, so wearers can also use natural peripheral vision from light entering from outside. Figure 1 of the paper by Frank G. Holz and colleagues shows the configuration and operating principle of PRIMA.

What does visual acuity measured with the special glasses represent?

The PRIMAvera trial, a prospective single-arm study conducted at 17 sites in five European countries, enrolled patients aged 60 or older with geographic atrophy from age-related macular degeneration in both eyes. Eligibility required visual acuity in the study eye of 20/320 or worse, atrophy larger than 2.4 mm in diameter, and a lesion extending to the fovea at the center of the retina. Thirty-eight patients received the implant, and 32 took part in the primary letter acuity assessment 12 months after surgery. The 12-month results by Holz and colleagues were peer reviewed and published in the New England Journal of Medicine (DOI: 10.1056/NEJMoa2501396). The trial is based mainly on comparison with preoperative measurements and was neither randomized nor blinded.

How finely patients could distinguish shapes through the chip was examined in a separate test of 33 patients 12 months after surgery. In this test, Landolt C rings with a gap were displayed directly on the special glasses, with no digital magnification. Residual natural vision, by contrast, was measured with the glasses removed and under best-corrected conditions. The average acuity of artificial vision, measured without using the camera or image processing, was 20/417 on the Snellen scale. The average natural visual acuity, measured without the special glasses, was almost unchanged from before surgery. Details of the measurement methods are in the PDF of the paper as published in NEJM (page 5).

In tests using the standard ETDRS letter chart, on the other hand, the brightness and magnification of the glasses can be adjusted from 1x to 12x. Because letters can be enlarged to be read, the test results include the assistive effect of image processing. The primary endpoint was being able to read 10 or more more letters than before surgery. Of the 32 patients evaluated 12 months after surgery, 26 reached this threshold (81.3%, 95% confidence interval 63.56–92.79%). The paper also statistically imputed data for the six patients whose measurements could not be obtained and estimated the proportion achieving the threshold across all 38 implanted patients at 79.9%.

AD

Surgical burden and what the 36-month follow-up shows

Postoperative reading ability may be influenced not only by assistance from the special glasses but also by training in using the device and by the passage of time. Because this trial was a single-arm before-and-after comparison, it is not possible to judge how much each factor contributed to the improvement. Of the 32 patients evaluated 12 months after surgery, 27 reported that they could read letters, numbers, and words using the device at home. However, a separate questionnaire examining the impact of visual impairment on daily life detected no change in behavior. The authors point out that the questionnaire may not have been sensitive enough for severe visual impairment.

Using PRIMA requires surgery to implant the device under the retina. In the safety analysis at 12 months, 19 of the 38 patients who underwent surgery experienced a total of 26 serious adverse events related to the surgery alone or to the surgery combined with the device. Of these, 21 occurred within two months of surgery, and events classified as severe included retinal detachment and macular holes. These results are summarized in the safety analysis and Table 2 of the paper by Holz and colleagues.

Results at 36 months come from follow-up data from the same PRIMAvera trial, which researcher Mahi Muqit presented at the EURETINA congress and which Science Corporation released on October 5, 2026. The results that can be confirmed in a peer-reviewed paper extend only to 12 months. In the efficacy assessment at 36 months published by the company, 14 of 18 patients reached a threshold equivalent to an improvement of 15 or more letters on the standard ETDRS chart. This means the acuity of artificial vision improved by 0.3 logMAR or more from before surgery. In the post hoc analysis in the peer-reviewed 12-month paper, 25 of 32 patients met the same improvement threshold.

However, the number of patients who could be evaluated fell by 36 months. Because the published materials do not give details of the measurement conditions or paired data for the same participants at both time points, the two sets of aggregate results alone do not show how much reading ability each individual patient maintained.

Safety was assessed in 27 patients at 36 months. According to the company, three serious adverse events occurred after the 12-month mark, but none was judged to be attributable to the device alone. No signs of new safety concerns were seen during this period, and the company said the remaining natural vision in the study eye and the condition of the implant site, confirmed by imaging, remained stable through 36 months. Details are explained in Science Corporation's announcement of the 36-month follow-up results.

A feasibility study with five participants was also conducted before PRIMAvera. In a peer-reviewed four-year follow-up study that Muqit and colleagues published in Ophthalmology Science in 2024, three patients evaluated with a standard letter chart from a distance of 1 m had their average number of letters read estimated using a model. Before surgery it was 11.7 letters; at 48 months it was 18.2 letters without the special glasses and 43.3 letters when using the glasses adjusted to the preferred magnification. However, the number of repeated measurements differed between before surgery and 48 months. In addition, some of the authors also took part in PRIMAvera, so the two papers do not provide data measured under the same conditions by independent research teams. The measurements are shown in Figure 6 of the four-year follow-up paper by Muqit and colleagues (DOI: 10.1016/j.xops.2024.100510).

Wider availability in Europe and preparing for US approval

On July 22, 2026, Science Corporation announced that it had obtained CE marking for PRIMA from DEKRA under the EU Medical Device Regulation (MDR). It said this makes sales possible in 30 European countries and announced the start of commercial rollout. As of July, applications for reimbursement of medical costs were being pursued in individual countries, and facilities to provide the device were being set up. On November 17, TechCrunch reported that PRIMA was already being offered in Germany.

In the US, the company announced in July that PRIMA had received two Humanitarian Use Device (HUD) designations from the US Food and Drug Administration (FDA). They cover patients who have lost vision in both eyes to advanced geographic atrophy from age-related macular degeneration, with no vision loss from other eye diseases, and patients who have lost vision to Stargardt disease.

Under the approval process described by the FDA, HUD designation is a prerequisite for applying for a Humanitarian Device Exemption (HDE), and marketing for the designated indication is permitted only after the HDE is approved. In its November funding announcement, Science Corporation said it aims to obtain US approval through this pathway.

In Europe, as reimbursement in individual countries and surgical facilities come into place, the range of patients who can use PRIMA will widen. For the start of US availability, the next milestone is whether HDE approval can be obtained for the targeted indications.